Navigating Market Cycles: Anti-Recession Logic and Innovation Dividends in the Gene Testing Industry

Amid the wave of precision medicine, the genetic testing industry is experiencing unprecedented opportunities and challenges. As a core pillar of precision medicine, genetic testing technology is seeing its applications continuously expand, with market demand becoming increasingly diversified. However, intensified industry competition, accelerated technological iteration, and increasingly stringent policy regulations have subjected genetic testing investments to complex cyclical fluctuations. How to navigate through the fog of market cycles, anchor long-term value, and identify recession-resistant logic and innovation dividends has become a focal point for the entire industry.

Amid a landscape marked by both opportunities and challenges, the genetic testing industry has reached a critical juncture in its development. On one hand, technological advancements and declining costs have laid the foundation for broader industry adoption; on the other, intensifying market competition and regulatory oversight have imposed higher demands on the industry’s sustainable growth.Against this backdrop, Chen Hao, Partner at Guoqian Venture Capital, delivered a presentation titled “Navigating Cycles: The ‘Recession-Resistant’ Logic and Innovation Dividends in Genetic Testing Investment” at the Precision Medicine and Molecular Diagnostics Industry Development Forum, part of the 2025 VBEF Future Healthcare & Pharma Top 100 Exhibition. He provided an in-depth analysis of his perspectives on current investment opportunities in genetic testing and his outlook on future development trends.

Chen Hao, Partner at Guoqian Venture Capital

The development of the genetic testing industry has been marked by numerous ups and downs. From its early technological inception to its widespread application today, each stage has presented both opportunities and challenges. Initially, genetic testing was primarily confined to scientific research; however, with technological maturation and cost reductions, it has gradually expanded into clinical applications. Chen Hao noted, “From the rise of non-invasive prenatal testing (NIPT) services in 2012 to the broad adoption of cancer screening and infectious disease testing, the genetic testing industry has experienced multiple peaks of development. Particularly during the COVID-19 pandemic, molecular diagnostics and genetic testing technologies garnered unprecedented attention and achieved significant advancement.”

However, the market overheating has also led to a bubble. The influx of substantial capital has intensified industry competition, placing immense pressure on enterprises.Chen Hao pointed out, “The market overheating in recent years led to a massive influx of capital, creating significant bubbles. Recently, market sentiment has softened, and companies are seeking new directions for development. Overall, however, this is not detrimental to the industry. Following the previous wave of substantial investment and production, costs in the genetic testing sector have continued to decline, while the increasing adoption of automation and AI technologies has improved testing efficiency and accuracy. Furthermore, raw material prices have dropped significantly in the post-pandemic era, and the strong performance of China’s manufacturing capabilities has spurred the emergence of automated platforms. Genetic testing has gradually evolved from an inaccessible technology into one that is widely accessible.”

Furthermore, the improvement of policy and regulatory oversight has provided safeguards for the healthy development of the industry. In recent years, national policy regulation has been continuously advancing. From the initial difficulties in approving PCR test kits to the current certification of innovative NGS products, regulatory breakthroughs have opened up new space for industry growth. The approval and market launch of a large number of innovative products have accelerated the industry’s progress toward commercialization.

Assessing the intrinsic value of technology, from the perspective of Western medicine, medical progress has been largely driven by advancements in equipment, industry, and chemistry. In a sense, the development of gene testing technologies and instruments will significantly propel medical advancement, playing a crucial role particularly in the fields of pathology and microbiology.

Overall, in the process of globalization of precision medicine, the genetic testing industry is facing dual opportunities and challenges: as a core support for precision medicine, its application areas continue to expand, and market demand is becoming increasingly diverse; meanwhile, intensified industry competition, accelerated technological iteration, and stricter policy regulations have collectively exacerbated cyclical fluctuations in the market. How to navigate through the fog of cycles and anchor long-term value has become the key to industrial breakthroughs.

In the current market environment, companies in the genetic testing industry need to embrace innovation and enhance their competitiveness to address the challenges posed by cyclical fluctuations.

First, genetic testing companies should closely integrate with innovative treatment solutions.Any diagnosis serves as a precursor; it gains greater significance only when integrated with treatment plans. For instance, the success of HPV testing lies not merely in the technology itself, but in its close alignment with cervical cancer follow-up protocols and vaccine development.

Secondly, the development of gene therapy and precision medicine has brought new opportunities to the genetic testing industry.The emergence of gene therapy drugs has provided new treatment options for certain genetic disorders, while genetic testing plays a crucial role in patient screening and treatment monitoring. By accurately detecting patients’ genetic mutations, tailored treatment plans can be developed to enhance therapeutic efficacy and reduce unnecessary healthcare expenditures. In 2025, several genetic testing products have already been approved as companion diagnostics for treatment regimens. Looking ahead, as treatment strategies continue to advance, the role of genetic testing in precision medicine will become increasingly prominent.

Furthermore,In the face of rising market demand and pressure from centralized procurement,Genetic testing companies need to increase throughput,Improve detection efficiency, reduce product costs, and ultimately meet market demands.At the same time, enterprises must also possess the capabilities for rapid R&D and high-speed response.to adapt to the rapid changes in the market.

Furthermore, genetic testing companies should actively participate in major global public health emergencies,To enhance one’s presence and influence, it is not advisable to focus solely on “making big money.” For instance, during global public health emergencies, genetic testing technology plays an indispensable role in pathogen identification and epidemic monitoring. By actively participating in such efforts, companies can demonstrate their technical prowess and social responsibility, thereby earning market recognition and trust.

Finally, enterprises need to select appropriate technology platforms to address practical issues.Chen Hao pointed out, “Not every technology needs to address monumental challenges; sometimes, solving a small problem can create immense value.” Enterprises should select technology platforms that align with their development strategies and market demands, focusing on resolving key issues in specific domains. When choosing a technology platform, companies should thoroughly consider factors such as technological maturity, market prospects, and cost-effectiveness to ensure the selected platform offers strong application value and growth potential.

In summary, with technological advancements, policy support, and market maturation, genetic testing will play an increasingly important role in precision medicine. Enterprises must continuously enhance their innovation capabilities and actively participate in industry development to achieve sustainable growth amidst cyclical fluctuations.